Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

Calvo, Emiliano; Vermorken, Jan B.; Hiret, Sandrine; Rodón, Jordi; Cortés, Javier; Senellart, Hélène; Brande, Jan Van den; Dyck, J.; Pétain, Aurélie; Ferré, Pierre; Bennouna, Jaafar

doi:10.1007/s00280-012-1856-4

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a future perspective, Calvo and coworkers conducted a phase I trial in patients with advanced malignancies to investigate the administration of VFL as hard capsules given twice a day on day 1-2 every day within 3-week cycles [Calvo et al 2012]. This approach has been shown feasible and the recommended dose for further investigations has been established at 270 mg/day.…”

Section: Ongoing Clinical Trials and Future Perspectivementioning

confidence: 99%

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience

Gerullis

Wawroschek

Köhne

et al. 2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.

show abstract

Section: Ongoing Clinical Trials and Future Perspectivementioning

confidence: 99%

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience

Gerullis

Wawroschek

Köhne

et al. 2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Anti-mitotic agents: Are they emerging molecules for cancer treatment?

Penna

Henriques

Bonatto

2017

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Vinflunine for the treatment of non-small cell lung cancer

Genova

Alama

Coco

et al. 2016

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Vinflunine belongs to the class of vinca alkaloids and acts by disrupting the microtubule dynamics during cell cycle; this agent is currently available for previously treated advanced transitional cell carcinoma in Europe. The aim of this invited review is to evaluate the potential role of vinflunine for the treatment of non-small cell lung cancer (NSCLC). Areas covered: The potential role of vinflunine in NSCLC is discussed on the basis of the available data, including full papers and meeting abstracts. Relevant preclinical studies describing the pharmacological properties of vinflunine are also included. The review also summarizes clinical studies, including phase I trials involving NSCLC among other tumors as well as phase II/III trials specifically addressing this malignancy. Additionally, the safety profile and the current regulatory status of vinflunine is discussed. Expert opinion: Vinflunine is active as single agent and as part of platinum-based combinations in NSCLC. It results non-inferior to docetaxel in a randomized phase III trial including previously treated NSCLC patients; additionally, its safety profile is generally considered manageable. Ultimately, further studies are needed to confirm the role of vinflunine in NSCLC, in consideration of the evolving evidence regarding targeted therapies and immune check-point inhibitors.

show abstract

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

Abstract: Repeated weekly administration of oral vinflunine is feasible and exhibits a moderate inter-individual PK variability. The MTD was achieved at 300 mg/day given for 2 consecutive days. According to the protocol rules, the RD was established at 270 mg/day.

Cited by 3 publications

References 17 publications

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience

Anti-mitotic agents: Are they emerging molecules for cancer treatment?

Vinflunine for the treatment of non-small cell lung cancer

Contact Info

Product

Resources

About